April 24 The CEO of Alexion, the Cheshire- based pharmaceutical company that makes the most expensive drug in the world, received $30.15 million in compensation last year, according to a federal filing Wednesday. Leonard Bell's Yale research, only has one product so far: Soliris. The drug treats ultra-rare diseases and generally insurers pay more
By a News Reporter-Staff News Editor at Politics& Government Week On the heels of a 2013 double-blind clinical trial which proved Axiom Food's Oryzatein plant-based brown rice protein equals animal-based whey in building and repairing muscles, Oryzatein has now become the very first brown rice protein to be granted GRAS approval. The GRAS appr
DEERFIELD, Ill.- Baxter International Inc. today announced that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE. "ADVATE has the widest range of dosage formulations, allowing for more precise customized dosing, and with the ADVATE with BAXJECT III reconstitution system, patients can prepare their treatment
April 23 Coral Gables- based Catalyst Pharmaceutical Partners soon will make its investigational drug Firdapse available at no cost to patients with a certain autoimmune disorder. Catalyst said it expects to submit an application for Firdapse's approval with the U.S. Food and Drug Administration next year. Catalyst has been leading the developmen
Mr. Gutman is an accomplished patent litigator, having frequently represented clients before trial and appellate courts, as well as arbitration panels. In the life sciences area, Mr. Gutman concentrates his practice on developing and executing market exclusivity and freedom-to-operate strategies, including patent office and FDA regulatory strategie
ALEXANDRIA, Va., April 24 Centrose, Madison, Wis., has been assigned a patent developed by Charles R. Hutchinson, Madison, Wis., Mohammed S. Shekhani, Madison, Wis., and James R. Prudent, Madison, Wis., for "glycoside compounds and pharmaceutical compositions thereof." The patent application was filed on Dec. 27, 2012. Written by Amal Ahmed; edit
Cynapsus Therapeutics Inc., a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot study of a single 25 mg sublingual strip dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug in the United States,..
April 24, 2014 TORONTO, CANADA- Cynapsus Therapeutics Inc., a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot study of a single 25 mg sublingual strip dose of apomorphine. APL-130277 is an easy-to- administer, fast-acting reformulation of apomorphine, which is the only appr
Upsher-Smith Laboratories, Inc.. a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, will highlight new pooled phase 1 data from studies in healthy adults comparing the adverse event profile of USL255 with immediate-release topiramate in a poster presentation at the 66
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has accepted the company's refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elviteg
Release date- 23042014- The U.S. Food and Drug Administration today approved Sylvant to treat patients with multicentric Castleman's disease, a rare disorder similar to lymphoma. 'Sylvant is the first FDA- approved drug to treat patients with MCD,' said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Ce
polyDNA's latest survey discovered that 72% of female respondents who had been vaccinated against the human papillomavirus, wanted to know if they still need to have a regular pap smear. "Already got immunized with the HPV vaccine? The formula of this natural antiviral product was shown to reduce HPV symptoms in a post-marketing clinical study tha
By a News Reporter-Staff News Editor at Women's Health Weekly In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer. The phase 2 data was presented in San Diego at the annual meeti
Release date- 23042014- Basel- Novartis announced today that it has reached a definitive agreement with GlaxoSmithKline plc to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK...
Healthcare market research firm Kalorama Information says the pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline.. The two drug makers will cooperate and among other transactions, Glaxo will buy Novartis's vaccine business and Novartis will gain Glaxo's oncology drug pipeline.
Patent Application Titled "Pharmaceutical Formulation Comprising an Antibody against P-Selectin and a Sugar Selected from Sucrose and Trehalose" Published Online. By a News Reporter-Staff News Editor at Politics& Government Week According to news reporting originating from Washington, D.C., by VerticalNews journalists, a patent application by the
Pharmacyclics, Inc. announced that data from the Phase III PCYC- 1112 study of single agent Imbruvica vs. ofatumumab, an established therapy in relapsed refractory CLL, as well as data from an Independent Efficacy Evaluation of Imbruvica after three years of follow-up, will be presented at the American Society of Clinical Oncology 50th Annual Meeti
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventor Pizzuto, Thomas J., filed on September 23, 2013, was made available online on April 10, 2014. No assignee for this patent application has been made. In the case of pharmaceuticals, wher
These non-approved uses of Risperdal were recently outlined* by the U.S. Justice Department and the Food and Drug Administration in the resolution of charges involving multimillion dollar criminal and civil penalties. The Justice Department and FDA issued a joint Nov. 4, 2013 press release* in which they explained the resolution of charges against.
ALEXANDRIA, Va., April 24 Tersus Pharmaceuticals, Mentor, Ohio, has been assigned a patent developed by Jeffrey Green, University Heights, Ohio, for "compositions and methods comprising C16: 1 n7-palmitoleate." The patent application was filed on March 2, 2012. Written by Kusum Sangma; edited by Jaya Anand.
ALEXANDRIA, Va., April 24 Wisconsin Alumni Research Foundation, Madison, Wis., has been assigned a patent developed by Gabriela G. Cezar, Middleton, Wis., for "reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds and other chemicals." The patent application was filed on April 10, 2007. Written
ALEXANDRIA, Va., April 24 Zurex Pharma, Middleton, Wis., has been assigned a patent developed by Stephen R. Ash, Lafayette, Ind., and Janusz Steczko, West Lafayette, Ind., for "antimicrobial compositions and methods of use." The patent application was filed on March 4, 2013. Written by Amal Ahmed; edited by Jaya Anand.
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors LIN, Wen Jen; Alai, Milind, filed on September 28, 2012, was made available online on April 10, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to National Taiwan University.
AbbVie today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50 th Annual Meeting of the American Society of Clinical Oncology, May 30- June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative therapies that improve
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, presented interim data demonstrating dose dependent increases in hemoglobin in patients with...